Cancer stromal targeting (CAST) therapy

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Current anticancer drugs lack tumor specificity, causing damage to normal tissues.
• Low molecular weight (MW) drugs cause adverse effects due to easy extravasation.
• High MW agents face diffusion challenges in stromal-rich tumors, limiting immunoconjugate therapy success.

Purpose of the Study:

• To present a novel therapeutic strategy overcoming limitations of existing anticancer drug delivery.
• To introduce Cancer-Stroma Targeting (CAST) therapy for effective treatment of solid tumors.

Main Methods:

• Conjugating small MW cytotoxic drugs with antibodies targeting tumor stroma components.
• Utilizing stroma-targeting immunoconjugates as a scaffold for sustained drug release.
• Evaluating the diffusion and efficacy of the cytotoxic agent throughout the tumor.

Main Results:

• Stroma-targeting immunoconjugates effectively bind to tumor stroma.
• Sustained release of cytotoxic agents from the immunoconjugate scaffold.
• Diffusion of the cytotoxic agent throughout the tumor, damaging both tumor cells and vessels.

Conclusions:

• Cancer-stroma targeting (CAST) therapy is a validated oncological treatment modality.
• CAST therapy is particularly effective for refractory, stromal-rich cancers.
• This strategy overcomes drawbacks of both low MW and high MW anticancer agents.